Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chin Hur

Showing results (191-200 of 254) with videos related to

Pageof 26
Sort By:
Cancer Reports (Hoboken, N.J.)|February 5, 2022
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patientsMyles A Ingram, Brianna N Lauren, Yoanna Pumpalova, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 1, 2014
Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagusPatrick Yachimski, Sachin Wani, Tonya Givens, et al.
Medicine|December 6, 2019
Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013Angela C Tramontano, Yufan Chen, Tina R Watson, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|August 26, 2018
Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation modelMary Linton B Peters, Andrew Eckel, Peter P Mueller, et al.
Cancer Medicine|June 4, 2026
The Impact of Pre-Existing Psychiatric Disorders on Gastric Cancer Stage and Mortality in Older AdultsJosephine Soddano, Sophie Wagner, Ji Yoon Yoon, et al.
Gastro Hep Advances|February 25, 2025
Initial Diagnostic Strategies for Helicobacter Pylori in Patients With Bleeding Peptic Ulcers Undergoing Endoscopy: A Cost-Effectiveness AnalysisMichael G Artin, Josephine Soddano, Sheila D Rustgi, et al.
Cancer|October 22, 2018
Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancerJacqueline N Chu, Jin Choi, Sassan Ostvar, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 21, 2011
The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation modelChung Yin Kong, Kevin J Nattinger, Tristan J Hayeck, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 10, 2025
The Cost-effectiveness of Gastric Cancer Screening and Surveillance Among Average-risk and Risk-stratified PopulationsMonika Laszkowska, Anne I Hahn, Stephanie King, et al.
Journal of Oncology|March 10, 2020
Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line SettingBrianna Lauren, Sassan Ostvar, Elisabeth Silver, et al.
Pageof 26

Showing results (191-200 of 254) with videos related to

Sort By:
Pageof 26
Cancer Reports (Hoboken, N.J.)|February 5, 2022
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patientsMyles A Ingram, Brianna N Lauren, Yoanna Pumpalova, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 1, 2014
Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagusPatrick Yachimski, Sachin Wani, Tonya Givens, et al.
Medicine|December 6, 2019
Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013Angela C Tramontano, Yufan Chen, Tina R Watson, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|August 26, 2018
Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation modelMary Linton B Peters, Andrew Eckel, Peter P Mueller, et al.
Cancer Medicine|June 4, 2026
The Impact of Pre-Existing Psychiatric Disorders on Gastric Cancer Stage and Mortality in Older AdultsJosephine Soddano, Sophie Wagner, Ji Yoon Yoon, et al.
Gastro Hep Advances|February 25, 2025
Initial Diagnostic Strategies for Helicobacter Pylori in Patients With Bleeding Peptic Ulcers Undergoing Endoscopy: A Cost-Effectiveness AnalysisMichael G Artin, Josephine Soddano, Sheila D Rustgi, et al.
Cancer|October 22, 2018
Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancerJacqueline N Chu, Jin Choi, Sassan Ostvar, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 21, 2011
The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation modelChung Yin Kong, Kevin J Nattinger, Tristan J Hayeck, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 10, 2025
The Cost-effectiveness of Gastric Cancer Screening and Surveillance Among Average-risk and Risk-stratified PopulationsMonika Laszkowska, Anne I Hahn, Stephanie King, et al.
Journal of Oncology|March 10, 2020
Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line SettingBrianna Lauren, Sassan Ostvar, Elisabeth Silver, et al.
Pageof 26